

Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia

John A. Gray² and Bryan L. Roth^{1,3}

²Department of Psychiatry, University of California, San Francisco, CA; ³Department of Pharmacology, University of North Carolina School of Medicine, 8032 Burnett-Womack, CB # 7365, Chapel Hill, NC 27599-7365

Cognitive impairment is a core feature of schizophrenia as deficits are present in the majority of patients, frequently precede the onset of other positive symptoms, persist even with successful treatment of positive symptoms, and account for a significant portion of functional impairment in schizophrenia. While the atypical antipsychotics have produced incremental improvements in the cognitive function of patients with schizophrenia, overall treatment remains inadequate. In recent years, there has been an increased interest in developing novel strategies for treating the cognitive deficits in schizophrenia, focusing on ameliorating impairments in working memory, attention, and social cognition. Here we review various molecular targets that are actively being explored for potential drug discovery efforts in schizophrenia and cognition. These molecular targets include dopamine receptors in the prefrontal cortex, nicotinic and muscarinic acetylcholine receptors, the glutamatergic excitatory synapse, various serotonin receptors, and the γ -aminobutyric acid (GABA) system.

Key words: serotonin/dopamine/glutamate/NMDA/
acetylcholine/GABA

Introduction

Schizophrenia is characterized by positive symptoms such as delusions and hallucinations, negative symptoms such as avolition and flat affect, and cognitive impairments. Although Kraepelin,¹ with his term “dementia praecox,” characterized the relationship between cognitive deficits and schizophrenia nearly a century ago, effective treatments for these deficits have not been developed. Cognitive dysfunction is estimated to occur in 75%–85% of patients with schizophrenia,² often precedes the onset of other symptoms,² and persists even after other

symptoms have been effectively treated.³ Indeed, a meta-analysis of cognitive deficits suggested that indices of cognitive deficits are much better predictors of functional outcome than indices from any other symptom domain.⁴ Furthermore, the severity of cognitive deficits is predictive of poorer medication compliance,⁵ overall treatment adherence,⁶ and increased tendency for relapse in first-episode patients.⁷

Until recently, antipsychotic drug development in schizophrenia has focused mainly on developing drugs that reduce the positive symptoms of schizophrenia,⁸ and indeed, all the current medications appear to be similar in efficacy for reducing positive symptoms in typical patients with schizophrenia.^{9,10} In a recent meta-analysis, patients treated with typical antipsychotics were actually shown to have small but detectable improvements in several cognitive domains¹¹; however, due to extrapyramidal side effects, many patients are also treated with anticholinergic agents that are well known to impair memory¹² and global cognitive ability.¹³ In addition, there is some evidence for the superiority of atypical antipsychotics, such as olanzapine and risperidone, over typicals in improving cognitive performance,^{14–16} though the benefits are relatively small and have not been consistently reproduced.¹⁷ Overall, the widespread use of the atypical antipsychotics has likely offered some cognitive benefit for patients with schizophrenia,¹⁸ though significant deficits persist, suggesting a need for directive treatments for enhancing cognition.

Due to the continued need for improved treatment of the cognitive impairments in schizophrenia, Wayne Fenton spearheaded the National Institutes of Mental Health’s joint academic and industry initiative termed MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) to facilitate the development of better treatments targeted at cognition.¹⁹ An initial MATRICS conference (<http://www.matrics.ucla.edu>) identified 7 primary cognitive domains that are crucial for developing targets for the treatment of cognition in schizophrenia. These domains included working memory, speed of processing, verbal learning and memory, attention and vigilance, reasoning and problem solving, visual learning and memory, and social cognition.^{20–22} An additional MATRICS conference (<http://www.matrics.ucla.edu>) identified pharmacologic strategies that hold promise for the treatment of impaired cognition in schizophrenia.

¹To whom correspondence should be addressed; tel: 919-966-7535, fax: 919-966-5640, e-mail: bryan_roth@med.unc.edu.

The primary molecular targets identified included dopamine receptors in the prefrontal cortex, nicotinic and muscarinic acetylcholine receptors, the glutamatergic excitatory synapse, various serotonin receptors, and the γ -aminobutyric acid (GABA) system. Below, we review many of the molecular targets being studied for potential drug development strategies aimed at enhancing cognition, both generally and specifically in schizophrenia (table 1).

Cholinergic Targets

Acetylcholine is known to play an important role not only in motor function but also in various domains of cognition, particularly attention, learning, and memory.²³ Indeed, cholinergic dysfunction has been shown to be central to the pathophysiology of Alzheimer's disease and has also been postulated to contribute to the cognitive deficits of various neuropsychiatric disorders, including schizophrenia.²³ The basal cholinergic complex sends widely diffuse afferents through 2 projections: the septohippocampal and the nucleus basalis of Meynart cortical pathways.²⁴ The septohippocampal pathway is important in working memory processes through hippocampal storage of intermediate-term memory,^{25,26} whereas the nucleus basalis of Meynart cortical pathway is involved in reference memory through long-term information storage in the neocortex.^{27,28} Additionally, a role for acetylcholine in the processes of attention has been demonstrated in rats and monkeys.²⁹ Pharmacologically, anticholinergic drugs, like scopolamine, produce learning impairments in healthy subjects similar to those of persons with dementia,³⁰ while cholinomimetic drugs, like physostigmine, can significantly enhance the memory functions of healthy individuals.^{30,31}

Although the degeneration of cholinergic neurons in the basal forebrain and the associated loss of cerebral neurotransmission that is seen in Alzheimer's disease are absent in schizophrenia,^{32,33} there is evidence of decreased nicotinic³⁴ and muscarinic³⁵ acetylcholine receptors in the cortex and hippocampus of individuals with schizophrenia. Interestingly, in patients with schizophrenia, decreased activity of choline acetyltransferase, a biosynthetic enzyme for acetylcholine production, was correlated with poorer cognitive functioning as measured by the Clinical Dementia Rating.³³ In addition, some of the atypical antipsychotics, but not typical antipsychotics, can increase the release of acetylcholine in the prefrontal cortex, possibly contributing to their modest enhancement of cognition in schizophrenia.³⁶ Thus, various targets within the cholinergic system are being investigated as potential enhancers of cognition in schizophrenia.

Cholinesterases

Cholinesterase inhibitors, such as donepezil and rivastigmine, are currently the main pharmacologic approach to

Table 1. Molecular Targets for Cognitive Enhancement in Schizophrenia

Molecular Target	Example Compound	Clinical Evidence
D ₁ agonists ^a	Dihydrexidine	Positive proof-of-concept trials
D ₄ antagonists	Sonepiprazole	Ineffective in acute schizophrenia
D ₄ agonists	A-412997	n/a
COMT inhibitors	Tolcapone	Improved cognition in Parkinson's disease
5-HT _{2A} antagonists	M100907	Modest efficacy in acute schizophrenia
5-HT _{1A} agonists	Tandospirone	Mixed results
5-HT _{1A} antagonists	WAY100635	n/a
5-HT ₄ agonists	Tegaserod	Recently withdrawn from market in IBS ^b
5-HT ₆ antagonists	SB-271046	n/a
5-HT ₇ agonists	No selective ligands	n/a
Cholinesterase inhibitors	Donepezil	Multiple trials, mixed results
Nicotinic α_7 agonists	DMXB-A	Positive proof-of-concept trials
Nicotinic $\alpha_4\beta_2$ agonists	RJR2403	n/a
M ₁ agonists	NDMC (nonselective)	Positive effects with nonselective agonists
M ₄ agonists	No selective ligands	n/a
M ₅ antagonists	No selective ligands	n/a
NMDA enhancers	Glycine	Multiple small trials, mostly positive
GlyT inhibitors	Org-24598	Positive proof-of-concept trials
Ampakines	CX-516	Mixed proof-of-concept trials
mGluR2/3 agonists	Unknown	Positive proof-of-concept trial reported
mGluR5 agonists	CDPPB	n/a
α_2 -adrenergic antagonists	Guanfacine	Positive small trials
GABA _A (α_2) agonists	TPA023	Single positive proof-of-concept trial
GABA _A (α_5) antagonists	L-655708	n/a
Sigma agonists	No selective ligands	n/a

Note: D, dopamine; n/a, clinical evidence not available to date; COMT, catechol-O-methyltransferase; 5-HT, serotonin; IBS, irritable bowel syndrome; DMXB-A, 3-2,4-dimethoxybenzylidene anabaseine; M, muscarinic; NMDA, N-methyl-D-aspartate; GlyT, glycine transporter; mGluR, metabotropic glutamate receptor; GABA, γ -aminobutyric acid.

^aThe term "agonist" is used here to refer to agonists, partial agonists, and positive allosteric modulators.

^bWithdrawn due to increase in adverse cardiovascular events.

the treatment of Alzheimer's disease and have been shown to slow the cognitive decline in this neurodegenerative disease.³⁷ As such, it has been proposed that cholinesterase inhibitors may also be useful in the treatment of the cognitive dysfunction in schizophrenia.³⁸ Acetylcholinesterase and butyrylcholinesterase are present in a wide variety of tissues and are broadly distributed in the brain. Inhibition of cholinesterases increases the synaptic concentration of acetylcholine, thereby enhancing and prolonging the action of acetylcholine on both muscarinic and nicotinic receptors. Therefore, cholinesterase inhibitors act as indirect cholinergic agonists at muscarinic and nicotinic receptors.

Following the administration of atypical antipsychotic treatment, cholinesterase inhibitors can increase the concentration of acetylcholine in the medial prefrontal cortex by 2- to 3-fold³⁶ and have been demonstrated to produce some functional normalization of brain activity during verbal fluency task performance of schizophrenic patients characterized by a significant increase in frontal lobe and cingulate activity on functional magnetic resonance imaging (fMRI).³⁹ As such, in recent years there have been multiple small randomized controlled trials of cholinesterase inhibitors in patients with schizophrenia, though results have been disappointing and inconsistent.⁴⁰ It has been suggested that the lack of consistent effects of cholinesterase inhibitors may be due to the high rate of cigarette smoking among patients with schizophrenia⁴¹ and subsequent desensitization of nicotinic receptors,⁴² thus rendering increased acetylcholine levels ineffective.⁴³ Indeed, galantamine, an acetylcholinesterase inhibitor that is also an allosteric potentiator of α_7 nicotinic receptors,^{44,45} does not cause α_7 receptor desensitization and has been shown to enhance cognitive functioning of schizophrenic patients in a 4-week double-blind placebo controlled trial.⁴⁶ Interestingly, galantamine produced cognitive enhancement in schizophrenic patients despite the fact that all the patients smoked at least 10 cigarettes per day.⁴⁶ Unfortunately, despite these initial positive findings, subsequent results with galantamine have been mixed.⁴⁷⁻⁴⁹ Thus, while pure cholinesterase inhibitors may be of minimal benefit for enhancing cognition in patients with schizophrenia, possibly due to desensitization of their α_7 nicotinic receptors from cigarette smoking, further study may be warranted with combined acetylcholinesterase inhibitors and allosteric potentiators of the nicotinic receptor in schizophrenia. However, it is likely that selective agents at various nicotinic and muscarinic receptors may be a more effective approach to developing drugs for treatment of the cognitive impairment in schizophrenia.

Nicotinic Receptors

It is well known that the smoking rates in individuals with schizophrenia are significantly higher than in the general population, and some have suggested that these individ-

uals may be "self-medicating" with nicotine.^{50,51} Indeed, nicotine administration has been shown to improve various measures of cognition that may ease some of the side effects of antipsychotic medications.⁵¹ For example, in patients with schizophrenia, a nicotine transdermal patch could dose dependently reverse haloperidol-induced impairments in working memory, attention, and reaction time⁵² and has been shown to reduce haloperidol-induced bradykinesia and rigidity compared with a placebo patch.⁵³ However, other studies have been mixed.⁵⁴ Interestingly, in one study,⁵⁵ some of the modest effects of cigarette smoking on clinical and cognitive outcome measures could also be improved by smoking denicotinized cigarettes, suggesting that nonnicotine components of cigarette smoke may also contribute.⁵⁵ Overall, while research on nicotinic treatment of individuals with schizophrenia has shown that, in single administrations, nicotine improves some aspects of cognition, additional administrations are not effective due to rapid desensitization of nicotinic receptors.⁴² Thus, considerable research is exploring the potential use of nicotinic agents, particularly partial agonists and allosteric modulators at various nicotinic receptor subunits that would be less likely to cause rapid receptor desensitization.

Nicotinic acetylcholine receptors are ionotropic receptors with a pentameric structure composed of alpha (α_2 to α_9) and beta (β_2 to β_4) subunits and are expressed at high levels in the hippocampus, cortex, striatum, and thalamus.^{34,56} The 2 most prevalent nicotinic receptors are the $\alpha_4\beta_2$, which is a high-affinity receptor, and the α_7 , which is a low-affinity nicotinic receptor, both of which have been shown to have reduced numbers in patients with schizophrenia.^{34,56} In addition, functional polymorphisms exist in the promoter region of the α_7 receptor that have shown genetic linkage in schizophrenia.^{57,58}

The α_7 nicotinic receptor subtype is a highly studied target for the development of drugs for cognitive enhancement. Studies in rodents have shown that antagonists at the α_7 nicotinic receptor induce sensory gating deficits similar to those seen in schizophrenia,⁵⁹ a hippocampal phenomenon manifested as an inability to attend appropriately to sensory stimuli.⁶⁰ Sensory gating deficits may strongly impact cognitive performance, and it has been shown that smoking transiently normalizes these sensory gating deficits.⁶⁰ In addition, agonists at α_7 receptors such as 3-2,4-dimethoxybenzylidene anabaseine (DMXB-A) can normalize the auditory gating deficits in rodents.⁶¹ Moreover, DMXB-A had a positive effect on a cognitive battery in a small proof-of-concept trial in humans,⁶² and additional clinical trials of α_7 receptor agonists are underway. However, there is concern that long-term use of α_7 agonists may induce the desensitization of nicotinic receptors, leading to a limited duration of efficacy.⁶³ Thus, further development of α_7 receptor partial agonists (eg, GTS-21) and allosteric potentiators (eg, galantamine) that induce minimal receptor desensitization is warranted.

In addition to α_7 receptors, it has been suggested that $\alpha_4\beta_2$ nicotinic receptors are involved in cognition.⁶⁴ Indeed, $\alpha_4\beta_2$ receptors are considered to represent more than 90% of the high-affinity nicotine-binding sites in the rat brain,⁶⁵ and decreased levels of $\alpha_4\beta_2$ receptor binding have been found in the hippocampus of patients with schizophrenia.⁵⁶ Furthermore, agonists of $\alpha_4\beta_2$ receptors, such as RJR2403 and SIB-1553A, can produce a significant and long-lasting improvement of memory in rats and monkeys.⁶⁶⁻⁶⁸ Additionally, $\alpha_4\beta_2$ agonists have been shown to stimulate the release of dopamine, norepinephrine, and acetylcholine in the hippocampus and frontal cortex in rats.⁶⁶ Thus, nicotinic $\alpha_4\beta_2$ receptor agonists may be of therapeutic benefit for the treatment of the cognitive deficits in schizophrenia by several mechanisms. In addition to α_7 and $\alpha_4\beta_2$ receptors, other nicotinic receptors, such as α_3 - and α_6 -containing receptors, may be involved in cognitive performance; however, studies are limited due to the lack of selective agonists and antagonists for these receptors.

Muscarinic Receptors

In addition to the ionotropic nicotinic receptors, numerous studies have implicated metabotropic muscarinic acetylcholine receptors in schizophrenia. Muscarinic receptors are G protein-coupled receptors⁶⁹ found widely throughout the central nervous system on both cholinergic and non-cholinergic cells where they function as both autoreceptors and heteroreceptors.⁷⁰⁻⁷² Of the 5 genetically distinct subtypes of muscarinic receptors (M_1 – M_5), the M_1 receptor has been most closely linked to cognition and schizophrenia.⁷³ Indeed, the M_1 receptor subtype is the most abundant of the muscarinic receptors in forebrain and hippocampus,^{74,75} brain regions crucial to normal cognitive functions. In addition, decreased M_1 receptor binding has been reported in postmortem studies of the prefrontal cortex, hippocampus, and striatum from patients with schizophrenia,⁷⁶⁻⁷⁸ that is, importantly, not due to chronic antipsychotic treatment.^{35,77,79} Interestingly, M_1 receptor-deficient mice demonstrate deficits in working memory and remote reference memory indicative of impaired hippocampal-cortical interactions.⁸⁰ Together, these results suggest that alterations in central M_1 receptors may have a role in the pathophysiology of schizophrenia and that M_1 receptor agonists may be beneficial in treating schizophrenia, particularly the cognitive impairments.⁷³

Action at M_1 receptors has been proposed to be a major contributor to the cognition-enhancing effects of clozapine,⁸¹ despite the fact that clozapine is an exceedingly weak partial agonist at M_1 and other muscarinic receptors.^{73,82} Thus, attention has focused on various clozapine metabolites including clozapine-*N*-oxide and *N*-desmethylclozapine (NDMC). Clozapine-*N*-oxide is inactive while NDMC has actions at many receptors (<http://pdsp.med.unc.edu/pdsp.php>).⁸² Interestingly,

NDMC is the major active metabolic of clozapine and has been reported to be a potent M_1 agonist that preferentially binds to M_1 receptors vs clozapine,⁸³ although more comprehensive studies fail to demonstrate selectivity of NDMC for M_1 receptors.⁸⁴ In addition, NDMC has high affinities for 5-HT_{2A} and 5-HT_{2C} receptors and is a partial agonist at D₂, D₃ receptors^{85,86} and δ -opioid receptors,⁸⁷ suggesting that this metabolite of clozapine may have antipsychotic and cognition-enhancing properties via a number of mechanisms. Furthermore, NDMC, but not clozapine, increases release of dopamine and acetylcholine in the prefrontal cortex and the hippocampus⁸⁸ and potentiates NMDA receptor activity in the hippocampus.⁸³ Thus, the cognitive enhancement observed with clozapine could actually be due to its metabolite NDMC via an uncertain mechanism.

Indeed, NDMC (ACP-104) and other M_1 receptor agonists are in clinical trials as potential treatments of the cognitive dysfunction in schizophrenia. Xanomeline, a nonselective M_1 and M_4 muscarinic agonist with potent actions at a variety of additional nonmuscarinic receptors including 5-HT_{1A} and 5-HT_{2A} receptors,⁸⁹ improved cognition and psychotic-like symptoms in Alzheimer's disease.⁹⁰ In addition, monotherapy with xanomeline resulted in an improvement of positive symptoms and cognitive function in 20 subjects with schizophrenia⁹¹ but was discontinued due to poor tolerability.⁹² The relatively nonselective actions of xanomeline and NDMC at a number of receptors (<http://pdsp.med.unc.edu/pdsp.php>) should engender caution among schizophrenia researchers for embracing positive data from xanomeline and NDMC studies as being specifically indicative of a role for M_1 receptors in schizophrenia.

Overall, evidence suggests that M_1 receptor agonists could be useful in treating various symptom domains in schizophrenia, though the roles of the other muscarinic receptor subtypes are less clear. M_5 receptors, for example, may be relevant to schizophrenia as they are located in the brainstem and midbrain, where they have an effect on dopamine release.⁹³ Indeed, xanomeline is also an antagonist at M_5 receptors, suggesting that blockade of M_5 may be involved in the benefits seen with xanomeline.⁹⁴ In addition, M_4 receptor knockout mice have impairments of cognitive performance and elevated levels of dopamine in the nucleus accumbens, suggesting a potential role for M_4 receptor agonists in treating both the positive and cognitive symptoms of schizophrenia.^{95,96} As selective agonists at muscarinic receptor subtypes have been difficult to develop, positive allosteric modulators are also being explored as potential therapeutic agents.

Glutaminergic Targets

Glutamate is the primary excitatory neurotransmitter for approximately 60% of the neurons in the mammalian brain, including all cortical pyramidal neurons,⁹⁷ and

plays a principal role in modulating long-term potentiation, a likely key cellular mechanism for learning and memory.^{98,99} Glutamate mediates fast excitatory postsynaptic potentials by acting on 3 ionotropic receptors, which are differentiated based upon sensitivity to the synthetic glutamate derivatives *N*-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate.¹⁰⁰ In addition, glutamate exerts slower modulatory effects by acting on various G protein-coupled metabotropic glutamate receptors (mGluRs).¹⁰¹ For example, mGluR2 and mGluR3 receptors modulate the release of glutamate, whereas the mGluR5 receptor potentiates the duration of NMDA receptor-dependent excitatory postsynaptic potentials.¹⁰²

It has been hypothesized for decades that some deficiency in NMDA function might play a role in the pathophysiology of schizophrenia.¹⁰³ Since the 1950s, the NMDA receptor antagonists phencyclidine (PCP) and ketamine were known to produce a large range of schizophrenia-like symptoms including psychotic symptoms,^{103–105} negative symptoms, and cognitive dysfunction,^{103–105} and it has been suggested that augmenting NMDA receptor activity may have therapeutic potential in schizophrenia.¹⁰⁰ Indeed, some of the atypical antipsychotics, but not typical antipsychotics, have been shown in preclinical models to reverse the effects of ketamine and PCP,^{106–109} presumably through indirect activation of NMDA receptors mediated by other neurotransmitter systems.⁸³ It is also important to note that a competing hypothesis suggests that a hyperactivity of glutamatergic neurotransmission is involved in the psychopathology of schizophrenia, leading to seemingly contradictory pharmacologic approaches being explored.¹⁰⁰ Indeed, glutamatergic excitotoxicity is thought to be a factor in the neurodegeneration of Alzheimer's disease¹¹⁰ and a weak NMDA receptor antagonist, memantine, has shown efficacy in slowing cognitive decline in moderate to advanced Alzheimer's disease.¹¹¹ Thus, the glutamate system, especially its NMDA-dependent components, is complex, and while small increases in NMDA-dependent glutamate neurotransmission might be cognitively enhancing, too much activation may result in neurodegeneration. Fortunately, the glutamatergic excitatory synapse offers multiple targets for drug development to provide the precise level of enhancement to improve cognition without excitotoxicity. Thus, we briefly review below various approaches being explored for modulating NMDA receptor neurotransmission and discuss approaches aimed at other glutamatergic mediators.

NMDA Receptors

NMDA glutamate receptors are ligand-gated ion channels with a primary glutamate-binding site and an allosteric glycine-binding site.¹⁰⁰ Interestingly, the opening of the NMDA channel appears to require both glutamate

and glycine binding, with glycine binding affecting channel open time and desensitization rate but not inducing channel opening itself.¹⁰⁰ In addition, NMDA receptor activity can be allosterically modulated by multiple other substances, including Mg²⁺, polyamines, and protons.¹¹² Thus, while direct agonists of the glutamate-binding site of the NMDA receptor may not be clinically feasible due to the risk of excess excitation and neurotoxicity, the allosteric sites on the NMDA receptor complex, particularly the glycine-binding site, are promising targets for drug development. Indeed, chronic treatment of rodents with glycine has not been found to induce excitotoxicity.^{113,114}

Compounds that target the glycine site of the NMDA receptor complex have been studied in multiple small clinical trials. These include glycine¹¹⁵ and D-serine,¹¹⁶ which are endogenous agonists at the glycine site of the NMDA receptor complex; D-alanine; and D-cycloserine, an antituberculosis drug that also binds to the glycine modulatory site where it functions as a partial agonist.¹¹⁷ In most of these studies, the test compound was administered along with either a typical or atypical antipsychotic, and there appears to be significant effects at reducing negative symptoms and cognitive impairment in patients with schizophrenia.¹¹⁸ Of the 4 agents, D-cycloserine has been the least efficacious, likely due to it being a partial agonist that acts as an antagonist at high doses. Interestingly, when used concurrently with clozapine, glycine¹¹⁹ and D-serine¹²⁰ have been reported to be ineffective while D-cycloserine seemed to worsen symptoms,¹²¹ possibly because clozapine may already enhance glycine and glutamate neurotransmission. Overall, agonists at the glycine allosteric site of the NMDA glutamate receptor hold promise in the treatment of the negative and cognitive symptoms of schizophrenia, possibly as an augmentation of currently existing antipsychotics. A potential limitation of targeting the glycine modulatory site is that the glycine site is probably half-saturated during physiologic conditions, suggesting that treatments targeting the glycine site would theoretically only be able to effectively double NMDA neurotransmission.¹¹⁸ In addition, both glycine and D-serine must be given at gram-level doses to significantly elevate central nervous system levels, and attempts to modify glycine or D-serine to produce synthetic glycine-site agonists, have, thus far, been unsuccessful. Thus, indirect approaches to activate NMDA receptors are being explored, such as increasing extracellular glycine and glutamate and by modulating AMPA receptors and mGluRs.

Glycine Transporters

An indirect approach being explored to boost NMDA activity via the glycine allosteric site is to increase synaptic glycine by inhibiting the glycine transporter. The glycine transporters, GlyT1 and GlyT2, have been identified on both neuronal and glial cells in the central nervous

system, where they are suggested to control the extracellular concentration of glycine.¹²² Thus, blockade of glycine transporters is predicted to increase extracellular glycine and thus enhance NMDA receptor neurotransmission. Indeed, preclinical data suggest that inhibition of glycine reuptake represents a feasible approach to enhance NMDA receptor activity and possibly be therapeutic in schizophrenia.¹⁰⁰ For example, selective, high-affinity inhibitors of the glycine transporter, including Org-24598, N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl] sarcosine, and SSR-504734, have been found to reverse PCP-induced hyperactivity and dopaminergic hyperreactivity in rodents.^{123,124} Furthermore, the glycine transport inhibitor glycyldodecylamide attenuated PCP-induced hyperactivity more potently than administration of glycine.^{125,126}

Clinical trials to date, however, have only studied the low-potency glycine transport inhibitor sarcosine (*N*-methyl glycine). In a clinical trial of sarcosine added to the stable antipsychotic regimen of patient with schizophrenia, there was a highly significant reduction in negative symptoms, along with smaller but significant reductions in positive and cognitive symptoms.¹²⁷ Interestingly, a subsequent study with patients on clozapine found no improvement of symptoms with the addition of sarcosine, a result similar to studies with the NMDA glycine site agonists.¹²⁸ These results strongly suggest a role of glycine transport inhibitors in the treatment of schizophrenia, though results of trials with selective, high-potency inhibitors are anticipated.

AMPA/Kainate Receptors

Another glutamatergic approach to drug development for cognitive enhancement in schizophrenia has been the development of compounds that stimulate AMPA and kainate glutamate receptors. AMPA and kainate receptors mediate the majority of the fast glutamatergic signaling in the brain, and AMPA receptors work heavily in concert with NMDA receptors.¹⁰⁰ AMPA receptors provide the primary depolarization necessary to activate NMDA receptors, while NMDA receptors are required for proper incorporation of AMPA receptors into the postsynaptic membrane, a process involved in synaptic plasticity.¹²⁹ Thus, activation of AMPA receptors is likely critically important for learning and memory; however, direct AMPA agonists are unlikely to be therapeutically useful as AMPA receptors rapidly desensitize after stimulation.¹³⁰

In an attempt to avoid desensitization of AMPA receptors, allosteric potentiators of AMPA receptor function, a class of compounds termed ampakines, are being studied as potential treatments for enhancing cognition in schizophrenia.^{131,132} Indeed, ampakines have been shown to enhance glutamatergic transmission and facilitate long-term potentiation in rodents.^{133,134} Furthermore,

ampakines improve performance in rodents on a variety of memory tasks including spatial mazes^{135,136} and learned fear¹³⁷ and have been shown to be effective in reducing age-associated memory deficits in rats.¹³⁸ In a clinical trial of schizophrenia patients on clozapine, coadministration of the ampakine CX-516 yielded significant improvements in memory and attention,¹³⁹ however, a trial of CX-516 as monotherapy in schizophrenia showed no clear beneficial effects.¹⁴⁰ Importantly, higher potency ampakines are currently under clinical development as both monotherapy for schizophrenia and adjunctive treatment for cognitive dysfunction, though results of trials are not yet available. A higher potency ampakine, farampator, has been tested in healthy elderly volunteers and improved short-term memory but appeared to impair episodic memory,¹⁴¹ and thus, it remains unclear if modulation of AMPA receptors has therapeutic value in the treatment of the cognitive dysfunction in schizophrenia although this is a highly active area of current research.

Metabotropic Glutamate Receptors

Agents acting at mGluRs, which serve to regulate glutamatergic neurotransmission both pre- and postsynaptically, are currently in preclinical development for treatment of the cognitive dysfunction in schizophrenia. There are 8 subtypes of mGluRs (mGluR1–8) which are categorized into 3 groups according to their second messenger-coupling and ligand-binding profiles with group I receptors (mGluR1 and mGluR5) primarily being studied for cognitive enhancement in schizophrenia.¹⁰² Group I receptors, particularly mGluR5, function predominantly to potentiate both presynaptic glutamate release and postsynaptic NMDA neurotransmission,¹⁴² and mGluR5 receptors show significant colocalization with NMDA receptors in cortical pyramidal neurons.¹⁴³ Together, these findings suggest that mGluR5 agonism may enhance NMDA activity and improve memory and cognition.¹⁴² Indeed, selective mGluR5 agonists were found to inhibit PCP-induced dopamine release in the rodent prefrontal cortex.¹⁴⁴ Direct mGluR5 agonists, however, are likely to induce receptor desensitization limiting their therapeutic usefulness. Thus, selective allosteric potentiators of mGluRs have recently been developed and hold promise as therapeutic agents.^{145,146} Indeed, preliminary positive results with an mGluR2/3 agonist in phase II trials have been reported (http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=916306&TICK=LLY&STORY=/www/story/12-07-2006/0004487009&EDATE=Dec+7,+2006).

Dopaminergic Targets

Dopamine projections to the prefrontal cortex comprising the mesocortical dopamine system are essential for normal cognition.^{147,148} Thus, it has been hypothesized

that decreased dopaminergic neurotransmission in the prefrontal cortex contributes to the cognitive deficits observed in schizophrenia, especially those related to executive functions and working memory.^{149–151} Indeed, postmortem and *in vivo* imaging studies have linked prefrontal dopamine dysfunction to cognitive impairment,^{151,152} and various studies have demonstrated that direct and indirect dopamine agonists can improve prefrontal cortex cognitive functions in humans.^{153,154} However, it seems that precise regulation of prefrontal dopaminergic tone is essential as, in addition to insufficient dopamine, excessive prefrontal dopamine (eg, resulting from acute stress) may be deleterious to cognition.^{155–157} Thus, dopamine function in the prefrontal cortex seems to follow an “inverted-U” dose-response curve whereby increases or decreases from an optimal level result in cognitive impairment.¹⁵⁸ Additionally, indirect dopamine agonists could potentially exacerbate psychosis by increasing neurotransmission at mesolimbic dopamine D₂ receptors.

D₁ Receptors

Dopamine D₁ receptors are expressed at high levels on the distal dendrites of pyramidal neurons in the prefrontal cortex that are thought to be involved in working memory processes.^{158,159} Indeed, evidence suggests an important role of dopamine D₁ receptors in the cognitive dysfunction of schizophrenia.¹³⁸ For example, there is a decreased level of D₁ receptor-like binding in the prefrontal cortex of drug-naïve patients with schizophrenia as measured with positron emission tomography imaging, and this decrease was found to be correlated with the severity of negative symptoms and cognitive dysfunction but not with the severity of positive symptoms.¹⁶⁰ In addition, in nonhuman primates, chronic blockade of D₂ receptors results in a downregulation of D₁ receptors in the prefrontal cortex and consequently produces severe impairments in working memory.¹⁶¹ This downregulation of D₁ receptors may explain why long-term treatment with typical antipsychotics can contribute to the cognitive dysfunction in schizophrenia. Thus, significant efforts are underway to examine the possible role of D₁ receptor agonists in treating cognitive dysfunction in schizophrenia. Indeed, low doses of selective D₁ agonists, such as dihydrexidine, A77636, and SKF81297, have cognition-enhancing actions in nonhuman primates,^{162–164} and short-term administration of the D₁ selective agonist, ABT-431, reversed the cognitive deficits in monkeys treated chronically with a D₂ receptor antagonist.¹⁶¹

Although novel compounds that, directly or indirectly, stimulate D₁ receptors may be of immense value in treating cognitive deficits in schizophrenia, several potential pitfalls may need to be overcome. First, D₁ receptor activity follows the “inverted-U” dose-response curve, where either too little or too much D₁ stimulation impairs

working memory.¹⁵⁸ In addition, chronic treatment with a D₁ agonist may actually lead to the downregulation of D₁ receptors which could, potentially, worsen cognition in the long term. Thus, an optimized level of D₁ receptor activation at the apex of the “inverted-U” may be required to obtain maximal cognitive benefits,¹⁵⁷ which may be accomplished by partial agonists or an intermittent pattern of administration.^{161,165} An additional obstacle is the powerful hypotensive effects of direct-acting D₁ agonists on peripheral D₁ receptors,¹⁶⁶ which may necessitate the use of indirect D₁-activating agents such as catechol-O-methyltransferase (COMT) inhibitors (see below).

D₄ Receptors

The high affinity of clozapine for dopamine D₄ receptors led to speculation that D₄ receptors may be clozapine’s “magic receptor.”¹⁶⁷ Clinical trials of selective D₄ antagonists, however, have not demonstrated any appreciable efficacy in the treatment of acute schizophrenia,^{168–170} though it is possible that D₄ receptor blockade in collaboration with action at other neurotransmitter receptors may be clinically beneficial. Indeed, studies of the physiological roles for the D₄ receptor are finding that D₄ receptors may play an important role in impulsivity and working memory.¹⁷¹

The mechanism by which D₄ blockade could improve cognition is not fully known,¹⁷² though D₄ receptors are present on both pyramidal neurons and GABA-producing interneurons in the prefrontal cortex and hippocampus,¹⁷³ areas important for cognitive function. Studies have demonstrated that activation of D₄ receptors decreases NMDA receptor activity in the hippocampus¹⁷⁴ and inhibits glutamatergic signaling in the prefrontal cortex.¹⁷⁵ Additionally, D₄ receptor knockout mice show enhanced activity of cortical pyramidal neurons, an effect mimicked in wild-type mice by administration of the D₄ antagonist PNU-101387G.¹⁷⁵ Together, these results suggest that D₄ antagonism may be a valuable approach to improve cognition in schizophrenia. Indeed, the D₄ antagonist NDG96-1 was reported to reverse PCP-induced deficits in object retrieval tasks in monkeys,¹⁷² and another D₄ antagonist, PNU-101387G, reversed deficits in the delayed response task induced by the pharmacologic stressor FG7142 (a benzodiazepine inverse agonist).¹⁷⁶ Interestingly, PCP-induced cognitive deficits are exacerbated by haloperidol, suggesting that strong blockade of other dopamine receptors may counter the beneficial effects of D₄ blockade on cognitive functioning.¹⁷²

Seemingly contradictory evidence also suggests that D₄ receptor agonists may improve cognitive function. For example, the selective D₄ agonist A-412997 showed dose-dependent improvement in social recognition in rats, a model of short-term memory,¹⁷⁷ and the D₄

agonist PD168077 was shown to facilitate memory consolidation of an inhibitory avoidance learned response in mice.¹⁷⁸ These effects have been hypothesized to be due to D₄ receptor modulation of inhibitory GABAergic signaling in the prefrontal cortex.¹⁷⁹ Indeed, the D₄ agonist PD168077 reduces GABA_A inhibitory currents in pyramidal neurons, which could be blocked by the D₄ antagonist L-745870 as well as clozapine.¹⁷⁹ Thus, in contrast to D₄ antagonist-induced enhancement of NMDA currents in the hippocampus, D₄ agonists may suppress GABA_A inhibitory currents in the prefrontal cortex and thereby indirectly enhance cortical excitability. Taken together, D₄ receptor-selective agents may be valuable in the treatment of the cognitive deficits in schizophrenia, though a balance between D₄ receptor modulation of prefrontal GABA_A and hippocampal NMDA receptors may be necessary.

Catechol-O-methyltransferase

COMT is a postsynaptic enzyme that methylates and thereby deactivates synaptically released catecholamines, particularly dopamine.¹⁸⁰ Historically, monoamine oxidase was considered the primary enzyme for the initial deactivation of synaptic dopamine,¹⁸¹ though mounting evidence suggests that COMT may be especially important for the breakdown of dopamine, particularly in the prefrontal cortex.¹⁸² For example, COMT knockout mice show increased baseline levels of dopamine, but not other catecholamines such as norepinephrine, specifically in the frontal cortex.¹⁸³ In addition, the COMT knockout mice also showed enhanced memory performance,¹⁸³ suggesting a potential role of COMT inhibition in improving cognition. Indeed, a selective, reversible inhibitor of COMT, tolcapone, has been reported to improve working memory in rodents¹⁸⁴ and has been shown to improve cognitive dysfunction in patients with advanced Parkinson's disease,¹⁸⁵ though use is limited due to a risk of liver failure.¹⁸⁶ Other COMT inhibitors are currently being investigated for treatment of the cognitive dysfunction in schizophrenia.

Interestingly, a common single nucleotide polymorphism in the gene encoding COMT, Val158Met, results in the transcription of a variant of the COMT enzyme with approximately 40% less enzymatic activity in humans.¹⁸⁷ The reduced COMT enzymatic activity associated with the Met variant presumably results in greater availability of dopamine in the prefrontal cortex and, thus, may improve cognition, hypotheses supported by findings from the COMT knockout mice,¹⁸³ and an fMRI study in humans.¹⁸⁸ Furthermore, the COMT locus at chromosome 22q11 has been identified as a susceptibility locus for schizophrenia in several linkage studies^{189,190} and 2 meta-analyses,^{189,191} though this remains controversial.¹⁹²⁻¹⁹⁴ However, accumulating evidence predicts that patients with schizophrenia who have the Met allele

may have improved cognitive response to clozapine.¹⁹⁵ Interestingly, a recent proof-of-concept experiment in normal human subjects treated with tolcapone demonstrated significant improvements on measures of executive function and verbal episodic memory in individuals with a Val/Val genotype but a diminished performance of individuals with the Met/Met genotype.¹⁹⁶ Thus, overall, the potential of pharmacologic inhibition of COMT in the long-term treatment of the cognitive dysfunction in schizophrenia remains to be determined.

Serotonergic Targets

5-HT_{2A} Receptors

5-HT_{2A} receptors are particularly abundant in the pyramidal neurons from cortical layer V,¹⁹⁷ where they have been described to colocalize with NMDA glutamate receptors,^{198,199} suggesting a role in modulating cognitive functions. Indeed, studies have demonstrated that 5-HT_{2A} receptors interact with postsynaptic density protein 95, a protein involved in anchoring NMDA receptors to postsynaptic densities,²⁰⁰ and it has been suggested that activation of 5-HT_{2A} receptors increases the release of glutamate onto pyramidal cells.²⁰¹ Interestingly, the selective 5-HT_{2A} receptor antagonist M100907 blocked the cognition-impairing effects of MK-801, an NMDA receptor antagonist.^{202,203} Similar findings have been reported for another 5-HT_{2A} antagonist AC-90179.²⁰⁴ Taken together, these studies suggest an intimate association between NMDA and 5-HT_{2A} receptors and imply that drugs with potent 5-HT_{2A} antagonistic actions may prove beneficial at improving cognition in schizophrenia, perhaps by normalizing NMDA receptor functioning.²⁰³

In addition, 5-HT_{2A} receptors are located on dopaminergic neurons in the ventral tegmental area,²⁰⁵ where they may modulate dopamine neuronal activity.²⁰⁶ Indeed, it is likely that a predominant role of 5-HT_{2A} receptors in antipsychotic action is to modulate dopaminergic tone, particularly along the mesocortical pathway.²⁰⁶⁻²⁰⁸ For example, clozapine, olanzapine, and ziprasidone, but not haloperidol or risperidone, can preferentially augment dopamine and norepinephrine release in the prefrontal cortex relative to the subcortical areas.²⁰⁹ In rats, however, repeated administration of the selective 5-HT_{2A} antagonist M100907 can alter the activity of midbrain dopamine neurons in rats, though there is disagreement as to whether cortical dopamine levels are potentiated²¹⁰ or inhibited.²¹¹ Thus, it has been hypothesized that the ultimate effect of 5-HT_{2A} antagonists on dopaminergic neurotransmission might be to stabilize it.^{208,212}

Clinical studies with selective 5-HT_{2A} receptor compounds have also demonstrated a role of 5-HT_{2A} receptors in cognitive functioning in schizophrenia. For example, in a study of 30 hospitalized patients with schizophrenia, administration of mianserin, a 5-HT_{2A/2C} and α_2 -adrenergic

antagonist, improved scores on the Automated Neuropsychological Assessment Metrics at 4 weeks, though no significant improvement was found on the Wisconsin Card Sorting Test.²¹³ These results suggest that 5-HT_{2A} receptor antagonism may improve cognitive function in schizophrenia,^{214,215} though additional clinical studies are needed. However, because nearly all approved atypical antipsychotic drugs have potent 5-HT_{2A} antagonist actions, it is unlikely that adding on a drug with potent 5-HT_{2A} antagonism will provide any significant boosting of cognition in treated patients.²¹² The potential cognition-enhancing effects resulting from 5-HT_{2A} receptor antagonism with the currently available atypical antipsychotics may be masked by other drug actions, such as anticholinergic effects, known to cause cognitive impairment.²¹⁶

5-HT_{1A} Receptors

5-HT_{1A} receptors are densely concentrated in the hippocampus, lateral septum, amygdala, and cortical limbic areas, as well as both the dorsal and median raphe nuclei.^{217,218} On raphe neurons, 5-HT_{1A} receptors function as somatic autoreceptors providing inhibitory feedback control of 5-HT release.²¹⁹ However, the highest concentrations of 5-HT_{1A} receptors are on cortical and hippocampal pyramidal neurons²²⁰ suggesting a role of 5-HT_{1A} receptors in mediating cognitive functions. 5-HT_{1A} receptors on cortical pyramidal neurons are colocalized with 5-HT_{2A} receptors,²²¹ though while 5-HT_{2A} receptor activation is excitatory, 5-HT_{1A} receptor activation inhibits pyramidal neurons.²²²

Because they act on different locations of the receptors, both 5-HT_{1A} partial agonists and full antagonists have shown a positive effect on cognitive activity in animals.²²³ Thus, 5-HT_{1A} partial agonists, presumably acting on pyramidal neurons, improve cognition in animals, while 5-HT_{1A} antagonists also improve cognition, probably by acting at the raphe autoreceptors.^{208,223} Indeed, atypical antipsychotic drugs modestly enhance cognition, and several atypical antipsychotic drugs have 5-HT_{1A} partial agonist actions (eg, aripiprazole, clozapine, olanzapine, ziprasidone, quetiapine),^{224,225} while others are 5-HT_{1A} antagonists (eg, risperidone and sertindole).²²⁴ Preclinical experiments also show that both 5-HT_{1A} partial agonists and antagonists can improve cognition. For example, intraprefrontal infusion of 8-OH-DPAT, a nonselective 5-HT_{1A} agonist, improved visual-spatial attention and decreased impulsivity in rats,²²⁶ while WAY100635, a 5-HT_{1A} antagonist, blocked the deleterious effects of MK-801 and NMDA antagonist in rats.²²⁷ Thus, the pre-clinical literature is mixed regarding whether 5-HT_{1A} agonists or antagonists enhance cognition.

Clinical data in humans are equally mixed. For example, activating 5-HT_{1A} receptors with a single dose of tandospirone, a 5-HT_{1A} partial agonist, diminished explicit memory function²²⁸ in demented patients, though chronic administration of tandospirone enhanced verbal memory

in patients with schizophrenia.^{229,230} Interestingly, the 5-HT_{1A} agonist NAE-086 actually induced hallucinations and nightmares in normal individuals after repeated doses,²³¹ suggesting that 5-HT_{1A} agonists may not be tolerated well in schizophrenic individuals. Taken together, these results demonstrate that additional clinical studies are needed but suggest that 5-HT_{1A} receptors may need to be differently modulated to optimally enhance cognition in various pathologic conditions (ie, dementia vs schizophrenia) and that 5-HT_{1A} partial agonists with a high level of efficacy may present a significant risk of exacerbating positive symptoms in schizophrenia.²³¹

5-HT₄ Receptors

Serotonin 5-HT₄ receptors are found at high densities in the hippocampus, frontal cortex, and amygdala, suggesting a role of these receptors in cognitive functions.^{232,233} Indeed, 5-HT₄ receptors have been shown to be markedly decreased in patients with Alzheimer's disease.²³⁴ In addition, 5-HT₄ receptor agonists have shown promise in the treatment of cognitive impairment by enhancing cholinergic transmission in the hippocampus.^{212,235} For example, a 5-HT₄ receptor partial agonist, SL65.0155, improved learning and memory performance in chemically induced rat model of amnesia,²³⁶ and this improvement may be due in part to lengthening of the excitatory postsynaptic potential in hippocampal CA1 pyramidal neurons.²³⁷ Interestingly, a recent study also showed that the activation of 5-HT₄ receptors in a neuronal culture inhibited the secretion of β -amyloid peptide and enhanced neuronal survival.²³⁸ Thus, while 5-HT₄ receptor-selective agonists are mostly being studied for their role in the treatment of Alzheimer's disease, they may also be of benefit in the treatment of the cognitive dysfunction in schizophrenia.

5-HT₆ Receptors

Several atypical antipsychotics, including clozapine and olanzapine, and some tricyclic antidepressants, such as amoxapine, amitriptyline, and clomipramine, were found to have high affinity for 5-HT₆ receptors²³⁹⁻²⁴¹ prompting significant efforts to understand its possible role in schizophrenia and other neuropsychiatric disorders. When anti-sense oligonucleotides were used to decrease the level of 5-HT₆ receptor expression in rats, the rats exhibited an increased number of yawns and stretches that could be blocked by atropine, suggesting a role of the 5-HT₆ receptor in the control of cholinergic neurotransmission.^{242,243} In addition, the selective 5-HT₆ receptor antagonist SB-271046 has been shown to improve memory retention in the water maze test of spatial learning and memory.^{244,245} Thus, it appears likely that 5-HT₆ receptors may have an important future role in the treatment of cognitive deficits in neuropsychiatric illnesses such as Alzheimer's disease and schizophrenia.²¹²

5-HT₇ Receptors

The 5-HT₇ receptor exhibits a distinct distribution in the central nervous system with relatively high levels in the thalamus, hypothalamus, and hippocampus and lower levels in the cortex and amygdala.^{246–248} In addition to possible roles in regulating circadian rhythms and sleep,^{249–251} 5-HT₇ receptors may also have an important role in hippocampus-dependent functions such as learning and memory.²⁵² For example, 5-HT₇ receptor knockout mice have been found to exhibit a specific impairment in contextual fear conditioning in which the animal learns to associate the environment with an aversive stimulus, a process generally believed to require the hippocampus.²⁵³ Electrophysiological studies have also shown that 5-HT₇ receptor activation modulates the excitability and intracellular signaling of pyramidal neurons in the CA1 region of the hippocampus.^{254,255} Additionally, in 5-HT₇ receptor knockout mice, there is a reduced ability to induce long-term potentiation in the CA1 region of the hippocampus.²⁵³ Together, these findings suggest an important role for the 5-HT₇ receptor in hippocampus-dependent functions, including learning and memory.²⁵² Thus, selective 5-HT₇ receptor activators might prove therapeutically useful for the treatment of the cognitive dysfunction of schizophrenia.²¹²

Other Neurotransmitter Targets

α_2 -Adrenergic Receptors

The central noradrenergic system projects from the locus ceruleus to the prefrontal cortex where α_2 -adrenergic receptors appear to play an important role in cognitive functioning.²⁵⁶ Indeed, treatment with the α_2 -adrenergic receptor agonists, clonidine and guanfacine, has been shown to improve cognitive performance without exacerbating positive symptoms in small trials of patients with schizophrenia.^{257,258} In addition, patients randomized to risperidone plus guanfacine showed significant improvement on tasks of working memory and attention compared with patients receiving typical antipsychotics plus guanfacine.²⁵⁸ However, clozapine and other atypicals have potent antagonist properties at α_2 -adrenergic receptors,²⁵⁹ which may contribute to the atypicality of atypicals by preferentially enhancing dopaminergic transmission in the frontal cortex over subcortical dopaminergic pathways.²⁶⁰ Indeed, combined treatment of a typical antipsychotic with the highly selective α_2 -adrenergic receptor antagonist, idazoxan, has been reported to produce a profile of antipsychotic activity similar to clozapine.²⁶¹ Thus, as α_2 -adrenergic receptor activity may be important in developing new drugs for schizophrenia that can improve cognition, balancing α_2 -adrenergic receptor activity to achieve both antipsychotic and procognitive efficacy may be challenging.

GABA_A Receptors

Appropriately synchronized GABA neurotransmission in the dorsolateral prefrontal cortex is required for adequate working memory,²⁶² suggesting that impairments in GABA-mediated inhibition could contribute to the cognitive impairments in schizophrenia. Indeed, postmortem studies have shown reduced GABAergic transmission in schizophrenia.^{263–265} In addition, recent observations^{266,267} have noted decreases in messenger RNA levels for glutamic acid decarboxylase 67, the synthetic enzyme for GABA, selectively in the prefrontal cortex of patients with schizophrenia. Interestingly, a recent study revealed that GABA alterations in the dorsolateral prefrontal cortex of schizophrenic patients may be restricted to certain cell classes, such as the chandelier cells, which synchronize the activation of pyramidal neurons via GABA_A receptor subtypes.²⁶⁸ Thus, the use of new benzodiazepine-like agents—selective for the α_2 subunit of the GABA_A receptor—in cognitive disorders could be both interesting and revealing. Indeed, there is evidence that reduced GABA neurotransmission in chandelier cells may be secondary to altered NMDA receptor function and could represent a “final common pathway” of prefrontal dysfunction in schizophrenia.²⁶⁹ Thus, drugs targeted to mitigate the disturbances in inhibition might be particularly effective in improving cognitive performance in schizophrenia. For example, positive allosteric modulators selective for GABA_A receptors containing α_2 subunits (eg, a GABA_A α_2 -selective benzodiazepine) may improve working memory function in schizophrenia.²⁷⁰ However, drugs that directly activate α_2 -containing GABA_A receptors independent of the presence of GABA may disrupt the critical synchronization of this circuit and impair working memory.²⁶⁹ In addition, activation of GABA_A receptors containing other subunits (eg, α_1 or α_5), such as by currently available benzodiazepines, may impair cognitive function. Indeed, a recent study in healthy volunteers showed that, contrary to lorazepam, a GABA_A α_2/α_3 subtype-selective partial agonist, TPA023, caused no detectable memory impairment.²⁷¹

As activation of GABA_A receptors containing α_5 subunits, such as by currently available benzodiazepines, may impair cognitive function and cause sedation, inhibitors of these receptors have been hypothesized to enhance cognition. Indeed, functionally selective inverse agonists at α_5 -containing GABA_A receptors have been demonstrated to enhance performance in animal models of cognition,^{272–274} apparently without lowering the seizure threshold as seen with nonselective GABA_A inverse agonists.^{274,275} In addition, α_5 subunit knockout mice demonstrate increased hippocampal activity due to the release of tonic GABAergic inhibition.²⁷⁶ Thus, antagonists or inverse agonists at α_5 -containing GABA_A receptors may hold promise in the treatment of the cognitive dysfunction in schizophrenia.

Neurosteroids and Sigma Receptors

The sigma (σ) receptor was initially designated as a subtype of opioid receptors²⁷⁷ but was later found to be a distinct pharmacological entity due to lack of binding of the classical opiate receptor antagonists naloxone and naltrexone.²⁷⁸ Indeed, when the $\sigma 1$ receptor was isolated and cloned, it was found to have no structural similarity to the opioid receptors.²⁷⁹ The functions of these receptors are poorly understood and endogenous ligands have yet to be identified, though it has been proposed that steroid hormones (eg, progesterone and testosterone), drugs of abuse (eg, cocaine, heroin, PCP), and psychiatric drugs (haloperidol, imipramine, and sertraline) may interact with σ receptors.^{280,281} In addition, it is well documented that $\sigma 1$ receptor ligands increase the NMDA receptor response in the hippocampus,^{282–284} suggesting a role in enhancing cognition. Indeed, $\sigma 1$ receptor agonists can reverse the memory impairments induced by the NMDA antagonists MK-801 in rodents.²⁸⁵

Neurosteroids, such as dehydroepiandrosterone (DHEA) and allopregnanolone, have been implicated in neuroprotection^{286–288} and enhancement of NMDA receptor neurotransmission,^{287,289,290} possibly through interaction with $\sigma 1$ receptors,²⁹⁰ suggesting therapeutic potential for enhancing cognition in schizophrenia. Consistent with the enhancement of NMDA neurotransmission, DHEA can enhance memory in rodents.^{291–294} In humans, a double-blind study of DHEA as an adjunct to antipsychotic treatment in chronic schizophrenic patients with prominent negative symptoms suggests some efficacy at improving negative symptoms, especially in women,²⁹⁵ though further studies are needed. Thus, neurosteroids may have therapeutic potential for improving the cognitive deficits observed in schizophrenia, though long-term treatment with steroids is problematic. In addition, while the contribution of σ receptor agonism to the actions of neurosteroids is not entirely known, highly selective σ receptor agonists are needed and hold therapeutic promise.

Potential Future Targets

There are a number of additional largely theoretical pharmacotherapeutic approaches for the treatment of cognition and schizophrenia. For example, significant progress has been made in recent years on elucidating various susceptibility genes in schizophrenia, including dysbindin, neuregulin 1, COMT, DISC1, and others.²⁹⁶ Interestingly, many of these genes appear to be related to the control of synaptic plasticity and glutamate transmission (particularly NMDA receptor function) and thus may allow for hypothesis-driven approaches for developing of actual disease-modifying drugs for schizophrenia and cognitive disorders.²⁹⁷ Another strategy involves the role of neurotrophic factors in the pathophysiology of

schizophrenia and the theory that schizophrenia may involve a neurodegenerative process.²⁹⁸ Neurotrophic factors, such as brain-derived neurotrophic factor, may play a role in neuronal and glial differentiation, proliferation, and regeneration and influence synaptic organization, neurotransmitter synthesis, and the maintenance of synaptic plasticity.^{299,300} Thus, strategies to enhance neurotrophic factor action may be able to prevent progression of schizophrenia.

Altering neurotransmitter signaling by targeting intracellular signaling cascades has long been suggested to be a future approach to novel therapeutic agents.³⁰¹ Though there has been concern about the feasibility of this approach, lithium is a signal transduction modifier that has been used safely for decades. Some targets being investigated include protein kinase C isoforms and glycogen synthase kinase 3.³⁰² In addition, subtype-selective phosphodiesterase (PDE) inhibitors, particularly at PDE10A, are actively being explored for the treatment of various symptom domains in schizophrenia.³⁰³ Another interesting approach at the receptor level would be developing ligands that differentially activate the various signaling pathways mediated by a single receptor, a process termed “functional selectivity”.³⁰⁴ Indeed, functional selectivity has been described in serotonin, opioid, dopamine, vasopressin, and adrenergic receptor systems³⁰⁴ and may be initiated by different ligand-induced conformational states, as shown for the β_2 -adrenergic receptor.³⁰⁵ Thus, the possibility of selecting or designing novel ligands that differentially activate only a subset of receptor functions is intriguing as an approach to drug discovery that may optimize therapeutic action.

Conclusions

Cognitive dysfunction is a major feature of schizophrenia that contributes significantly to the long-term functional impairment that patients experience. While the past half-century of antipsychotic development has had a profound effect on the treatment of schizophrenia, the cognitive deficits in schizophrenia have been insufficiently addressed. Therefore, it is critical to continue the pursuit of diverse molecular targets for discovering new pharmacotherapeutic agents for the treatment of schizophrenia. For the past 20 years, psychopharmacologic research in schizophrenia has aimed for the development of new antipsychotic drugs with a more rapid onset of action, lower risk of side effects, and improved efficacy in the domains of negative and cognitive symptoms from a single compound. Currently, however, it seems unlikely that a single drug will have the desired effect across all these domains, and thus, optimal treatment of schizophrenia will likely rely on individualized polypharmacy and augmentation strategies. The ultimate goal, of course, will be the development of “cure therapeutics”,²⁹⁷ which will require significant advances in our understanding of the

underlying pathophysiology of schizophrenia, highlighting the need for continued basic research efforts at identifying and validating diverse and novel molecular targets.

Funding

National Institutes of Health (RO1MH61887 to B.R., RO1MH57635 to B.R.); National Institute of Mental Health (NO1MH32004 to B.R.).

References

1. Kraepelin E. *Dementia Praecox and Paraphrenia [1919]*. New York, NY: Robert E. Krieger; 1971.
2. Reichenberg A, Weiser M, Caspi A, et al. Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. *J Clin Exp Neuropsychol*. 2006;28:193–207.
3. Heinrichs RW. The primacy of cognition in schizophrenia. *Am Psychol*. 2005;60:229–242.
4. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry*. 1996;153:321–330.
5. Burton SC. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. *J Psychiatr Pract*. 2005;11:369–378.
6. Prouteau A, Verdoux H, Briand C, et al. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. *Schizophr Res*. 2005;77:343–353.
7. Chen EY, Hui CL, Dunn EL, et al. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. *Schizophr Res*. 2005;77:99–104.
8. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Mol Psychiatry*. 2005;10:79–104.
9. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*. 2005;353:1209–1223.
10. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. *Lancet*. 2003;361:1581–1589.
11. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. *Biol Psychiatry*. 2004;55:1013–1022.
12. Strauss ME, Reynolds KS, Jayaram G, Tune LE. Effects of anticholinergic medication on memory in schizophrenia. *Schizophr Res*. 1990;3:127–129.
13. Davidson M, Harvey PD, Powchik P, et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. *Am J Psychiatry*. 1995;152:197–207.
14. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. *Am J Psychiatry*. 2002;159:1018–1028.
15. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. *Am J Psychiatry*. 2001;158:176–184.
16. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. *Arch Gen Psychiatry*. 2000;57:249–258.
17. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. *Schizophr Bull*. 1999;25:201–222.
18. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. *Int J Neuropsychopharmacol*. 2005;8:457–472.
19. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. *Schizophr Res*. 2004;72:5–9.
20. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. *Schizophr Res*. 2004;72:29–39.
21. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. *Neuropsychopharmacology*. 2006;31:2033–2046.
22. Bowie CR, Harvey PD. Cognition in schizophrenia: impairments, determinants, and functional importance. *Psychiatr Clin North Am*. 2005;28:613–633, 626.
23. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. *Psychopharmacology (Berl)*. 2004;174:45–53.
24. Woolf NJ, Butcher LL. Cholinergic systems in the rat brain: IV. Descending projections of the pontomesencephalic tegmentum. *Brain Res Bull*. 1989;23:519–540.
25. Brito GN, Davis BJ, Stopp LC, Stanton ME. Memory and the septo-hippocampal cholinergic system in the rat. *Psychopharmacology (Berl)*. 1983;81:315–320.
26. Fadda F, Melis F, Stancampiano R. Increased hippocampal acetylcholine release during a working memory task. *Eur J Pharmacol*. 1996;307:R1–R2.
27. Dunnett SB. Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. *Psychopharmacology (Berl)*. 1985;87:357–363.
28. Meck WH, Church RM, Wenk GL, Olton DS. Nucleus basalis magnocellularis and medial septal area lesions differentially impair temporal memory. *J Neurosci*. 1987;7:3505–3511.
29. Robbins TW, Everitt BJ, Marston HM, Wilkinson J, Jones GH, Page KJ. Comparative effects of ibotenic acid- and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. *Behav Brain Res*. 1989;35:221–240.
30. Sitaram N, Weingartner H, Gillin JC. Human serial learning: enhancement with arecholine and choline impairment with scopolamine. *Science*. 1978;201:274–276.
31. Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS. Physostigmine: improvement of long-term memory processes in normal humans. *Science*. 1978;201:272–274.
32. el-Mallakh RS, Kirch DG, Shelton R, et al. The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. *J Neuropsychiatry Clin Neurosci*. 1991;3:383–386.

33. Powchik P, Davidson M, Haroutunian V, et al. Postmortem studies in schizophrenia. *Schizophr Bull*. 1998;24:325–341.
34. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. *Biol Psychiatry*. 1995;38:22–33.
35. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. *Mol Psychiatry*. 2002;7:1083–1091.
36. Ichikawa J, Dai J, O’Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. *Neuropsychopharmacology*. 2002;26:325–339.
37. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. *Cochrane Database Syst Rev*. 2006;1:CD005593.
38. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. *Biol Psychiatry*. 1999;45:1–16.
39. Nahas Z, George MS, Horner MD, et al. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. *Neurocase*. 2003;9:274–282.
40. Ferreri F, Agbokou C, Gauthier S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. *J Psychiatry Neurosci*. 2006;31:369–376.
41. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. *Am J Psychiatry*. 1986;143:993–997.
42. Benwell ME, Balfour DJ, Birrell CE. Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine. *Br J Pharmacol*. 1995;114:454–460.
43. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. *Biol Psychiatry*. 2002;51:349–357.
44. Maelicke A, Schrattenholz A, Storch A, et al. Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction. *J Recept Signal Transduct Res*. 1995;15:333–353.
45. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. *Mol Pharmacol*. 1996;49:1–6.
46. Allen T, McEvoy JP, Keefe RS, Levin ED, Wilson W. Galantamine as an adjunctive therapy in the treatment of schizophrenia. Paper presented at: 11th Congress of the International Psychogeriatric Association (IPA); August 17–22, 2003; Chicago, Ill.
47. Bora E, Veznedaroglu B, Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. *Clin Neuropharmacol*. 2005;28:139–141.
48. Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. *Int Clin Psychopharmacol*. 2007;22:63–68.
49. Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. *Biol Psychiatry*. 2006;60:530–533.
50. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. *Am J Psychiatry*. 1998;155:1490–1501.
51. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. *Neurosci Biobehav Rev*. 2005;29:1021–1034.
52. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. *Neuropsychopharmacology*. 1996;15:429–436.
53. Yang YK, Nelson L, Kamaraju L, Wilson W, McEvoy JP. Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. *Neuropsychopharmacology*. 2002;27:684–686.
54. Sacco KA, Termine A, Seyal A, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. *Arch Gen Psychiatry*. 2005;62:649–659.
55. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. *Neuropsychopharmacology*. 2002;27:479–497.
56. Breese CR, Lee MJ, Adams CE, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. *Neuropsychopharmacology*. 2000;23:351–364.
57. Freedman R, Coon H, Myles-Worsley M, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. *Proc Natl Acad Sci USA*. 1997;94:587–592.
58. Riley BP, Makoff A, Mogudi-Carter M, et al. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. *Am J Med Genet*. 2000;96:196–201.
59. Luntz-Leybman V, Bickford PC, Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. *Brain Res*. 1992;587:130–136.
60. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. *Am J Psychiatry*. 1993;150:1856–1861.
61. Simosky JK, Stevens KE, Kem WR, Freedman R. Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. *Biol Psychiatry*. 2001;50:493–500.
62. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. *Arch Gen Psychiatry*. 2006;63:630–638.
63. Simosky JK, Stevens KE, Freedman R. Nicotinic agonists and psychosis. *Curr Drug Targets CNS Neurol Disord*. 2002;1:149–162.
64. Schreiber R, Dalmus M, De Vry J. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. *Psychopharmacology (Berl)*. 2002;159:248–257.
65. Flores CM, Rogers SW, Pubreza LA, Wolfe BB, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. *Mol Pharmacol*. 1992;41:31–37.
66. Bontempi B, Whelan KT, Risbrough VB, et al. SIB-1553A, (+)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates. *J Pharmacol Exp Ther*. 2001;299:297–306.
67. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological

specification, and anatomic localization. *Psychopharmacology (Berl)*. 2006;184:523–539.

68. Lloyd GK, Menzaghi F, Bontempi B, et al. The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. *Life Sci*. 1998;62: 1601–1606.
69. Felder CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. *FASEB J*. 1995;9: 619–625.
70. Raiteri M, Leardi R, Marchi M. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. *J Pharmacol Exp Ther*. 1984;228:209–214.
71. Wamsley JK, Zarbin MA, Kuhar MJ. Distribution of muscarinic cholinergic high and low affinity agonist binding sites: a light microscopic autoradiographic study. *Brain Res Bull*. 1984;12:233–243.
72. Vizi ES, Kobayashi O, Torocsik A, et al. Heterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release. *Neuroscience*. 1989;31:259–267.
73. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. *Mol Psychiatry*. 2007;12:232–246.
74. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. *J Neurosci*. 1991;11:3218–3226.
75. Wei J, Walton EA, Milici A, Buccafusco JJ. m1-m5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. *J Neurochem*. 1994;63:815–821.
76. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. *Biol Psychiatry*. 2000;48:381–388.
77. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. *Am J Psychiatry*. 2001;158:918–925.
78. Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. *Mol Psychiatry*. 1996;1:54–58.
79. Watanabe S, Nishikawa T, Takashima M, Toru M. Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. *Life Sci*. 1983;33:2187–2196.
80. Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. *Nat Neurosci*. 2003;6:51–58.
81. Bymaster FP, Felder C, Ahmed S, McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. *Curr Drug Targets CNS Neurol Disord*. 2002;1:163–181.
82. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proc Natl Acad Sci USA*. 2007;104:5163–5168.
83. Sur C, Mallorga PJ, Wittmann M, et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. *Proc Natl Acad Sci USA*. 2003;100:13674–13679.
84. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? *Psychopharmacology (Berl)*. 2005;178:451–460.
85. Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. *J Pharmacol Exp Ther*. 2005;315:1278–1287.
86. Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. *Psychopharmacology (Berl)*. 2004;177:207–216.
87. Onali P, Olianas MC. N-Desmethylclozapine, a major clozapine metabolite, acts as a selective and efficacious [delta]-opioid agonist at recombinant and native receptors. *Neuropsychopharmacology*. 2006;32:773–785.
88. Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. *Neuropsychopharmacology*. 2005;30:1986–1995.
89. Watson J, Brough S, Coldwell MC, et al. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. *Br J Pharmacol*. 1998;125: 1413–1420.
90. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. *Arch Neurol*. 1997;54:465–473.
91. Shekhar A, Potter WZ, Lienemann J, et al. Efficacy of xanomeline, a selective muscarinic agonist, in treating schizophrenia: a double-blind, placebo controlled study. Paper presented at: American College of Neuropsychopharmacology, 2001; Hawaii, Hawaii.
92. Mirza NR, Peters D, Sparks RG. Xanomeline and the anti-psychotic potential of muscarinic receptor subtype selective agonists. *CNS Drug Rev*. 2003;9:159–186.
93. Miller AD, Blaha CD. Midbrain muscarinic receptor mechanisms underlying regulation of mesoaccumbens and nigrostriatal dopaminergic transmission in the rat. *Eur J Neurosci*. 2005;21:1837–1846.
94. Grant MK, El-Fakahany EE. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor. *J Pharmacol Exp Ther*. 2005;315:313–319.
95. Tzavara ET, Bymaster FP, Davis RJ, et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. *FASEB J*. 2004; 18:1410–1412.
96. Tzavara ET, Bymaster FP, Felder CC, et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. *Mol Psychiatry*. 2003;8:673–679.
97. Nieuwenhuys R. The neocortex. An overview of its evolutionary development, structural organization and synaptology. *Anat Embryol (Berl)*. 1994;190:307–337.
98. Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. *J Physiol*. 1973; 232:331–356.
99. Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. *Neuron*. 2004;44:5–21.
100. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. *Mol Psychiatry*. 2004;9:984–997, 979.

101. Nicoletti F, Meek JL, Iadarola MJ, Chuang DM, Roth BL, Costa E. Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus. *J Neurochem*. 1986;46:40–46.
102. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. *Psychopharmacology (Berl)*. 2004;174:39–44.
103. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. *Clin Pharmacol Ther*. 1965;6:279–291.
104. Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. *Hillside J Clin Psychiatry*. 1987;9:12–35.
105. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. *J Psychiatr Res*. 1999;33:523–533.
106. Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. *Psychopharmacology (Berl)*. 1995;122:198–201.
107. Corbett R, Camacho F, Woods AT, et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. *Psychopharmacology (Berl)*. 1995;120:67–74.
108. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. *J Pharmacol Exp Ther*. 2000;293:8–14.
109. Wang RY, Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. *Neuropsychopharmacology*. 1998;19:74–85.
110. Chohan MO, Iqbal K. From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease. *J Alzheimers Dis*. 2006;10:81–87.
111. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med*. 2003;348:1333–1341.
112. Yamakura T, Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. *Prog Neurobiol*. 1999;59:279–298.
113. Shoham S, Javitt DC, Heresco-Levy U. High dose glycine nutrition affects glial cell morphology in rat hippocampus and cerebellum. *Int J Neuropsychopharmacol*. 1999;2:35–40.
114. Shoham S, Javitt DC, Heresco-Levy U. Chronic high-dose glycine nutrition: effects on rat brain cell morphology. *Biol Psychiatry*. 2001;49:876–885.
115. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. *Nature*. 1987;325:529–531.
116. Mothet JP, Parent AT, Wolosker H, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. *Proc Natl Acad Sci USA*. 2000;97:4926–4931.
117. Hood WF, Compton RP, Monahan JB. D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. *Neurosci Lett*. 1989;98:91–95.
118. Javitt DC. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. *Curr Opin Psychiatry*. 2006;19:151–157.
119. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. *Am J Psychiatry*. 2000;157:826–828.
120. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. *Am J Psychiatry*. 1999;156:1822–1825.
121. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. *Am J Psychiatry*. 1996;153:1628–1630.
122. Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. *Proc Natl Acad Sci USA*. 1998;95:15730–15734.
123. Aubrey KR, Vandenberg RJ. N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. *Br J Pharmacol*. 2001;134:1429–1436.
124. Brown A, Carlyle I, Clark J, et al. Discovery and SAR of org 24598-a selective glycine uptake inhibitor. *Bioorg Med Chem Lett*. 2001;11:2007–2009.
125. Javitt DC, Sershen H, Hashim A, Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. *Neuropsychopharmacology*. 1997;17:202–204.
126. Javitt DC, Frusciante M. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. *Psychopharmacology (Berl)*. 1997;129:96–98.
127. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. *Biol Psychiatry*. 2004;55:452–456.
128. Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. *Biol Psychiatry*. 2006;60:645–649.
129. Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. *Psychopharmacology (Berl)*. 2005;179:154–163.
130. Suppiramaniam V, Bahr BA, Sinnarajah S, et al. Member of the Ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors. *Synapse*. 2001;40:154–158.
131. Yamada KA. Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? *Neurobiol Dis*. 1998;5:67–80.
132. Arai A, Kessler M, Xiao P, Ambros-Ingerson J, Rogers G, Lynch G. A centrally active drug that modulates AMPA receptor gated currents. *Brain Res*. 1994;638:343–346.
133. Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. *J Neurosci*. 1998;18:2740–2747.
134. Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. *J Neurosci*. 1998;18:2748–2763.
135. Granger R, Staubli U, Davis M, et al. A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. *Synapse*. 1993;15:326–329.
136. Staubli U, Perez Y, Xu FB, et al. Centrally active modulators of glutamate receptors facilitate the induction of long-term

potentiation in vivo. *Proc Natl Acad Sci USA*. 1994;91: 11158–11162.

137. Lebrun C, Pilliere E, Lestage P. Effects of S 18986-1, a novel cognitive enhancer, on memory performances in an object recognition task in rats. *Eur J Pharmacol*. 2000;401:205–212.
138. Granger R, Deadwyler S, Davis M, et al. Facilitation of glutamate receptors reverses an age-associated memory impairment in rats. *Synapse*. 1996;22:332–337.
139. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. *J Clin Psychopharmacol*. 2001;21:484–487.
140. Marenco S, Egan MF, Goldberg TE, et al. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. *Schizophr Res*. 2002;57:221–226.
141. Wezenberg E, Jan Verkes R, Ruigt GSF, Hulstijn W, Sabbe BGC. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. *Neuropsychopharmacology*. 2007;32:1272–1283.
142. Chavez-Noriega LE, Schaffhauser H, Campbell UC. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. *Curr Drug Targets CNS Neurol Disord*. 2002;1:261–281.
143. Alagarsamy S, Rouse ST, Junge C, et al. NMDA-induced phosphorylation and regulation of mGluR5. *Pharmacol Biochem Behav*. 2002;73:299–306.
144. Maeda J, Suhara T, Okauchi T, Semba J. Different roles of group I and group II metabotropic glutamate receptors on phencyclidine-induced dopamine release in the rat prefrontal cortex. *Neurosci Lett*. 2003;336:171–174.
145. Marino MJ, Conn PJ. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. *Curr Opin Pharmacol*. 2006;6:98–102.
146. Govek SP, Bonnefous C, Hutchinson JH, et al. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia. *Bioorg Med Chem Lett*. 2005;15:4068–4072.
147. Aalto S, Bruck A, Laine M, Nagren K, Rinne JO. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. *J Neurosci*. 2005;25:2471–2477.
148. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. *Science*. 1979;205:929–932.
149. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. *Am J Psychiatry*. 1991;148:1474–1486.
150. Doran AR, Boronow J, Weinberger DR, Wolkowitz OM, Breier A, Pickar D. Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. *Neuropsychopharmacology*. 1987;1:25–32.
151. Weinberger DR, Berman KF, Illowsky BP. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. *Arch Gen Psychiatry*. 1988;45:609–615.
152. Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. *J Neurosci*. 2002;22:3708–3719.
153. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. *Schizophr Res*. 2005;77:43–58.
154. Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. *Nature*. 1995;378:180–182.
155. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. *J Neurosci*. 2000;20:1208–1215.
156. Mattay VS, Callicott JH, Bertolino A, et al. Effects of dextroamphetamine on cognitive performance and cortical activation. *Neuroimage*. 2000;12:268–275.
157. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. *Nature*. 1995;376:572–575.
158. Goldman-Rakic PS, Muly EC III, Williams GV. D(1) receptors in prefrontal cells and circuits. *Brain Res Brain Res Rev*. 2000;31:295–301.
159. Fremeau RT Jr, Duncan GE, Fornaretto MG, et al. Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. *Proc Natl Acad Sci USA*. 1991;88:3772–3776.
160. Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. *Nature*. 1997;385:634–636.
161. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. *Science*. 2000;287: 2020–2022.
162. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. *Psychopharmacology (Berl)*. 1994;116:143–151.
163. Cai JX, Arnsten AF. Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. *J Pharmacol Exp Ther*. 1997;283:183–189.
164. Schneider JS, Sun ZQ, Roeltgen DP. Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. *Brain Res*. 1994;663:140–144.
165. Castner SA, Goldman-Rakic PS. Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. *J Neurosci*. 2004;24:1446–1450.
166. Pellissier G, Demenge P. Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists. *J Cardiovasc Pharmacol*. 1991;18:548–555.
167. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. *Nature*. 1991;350:610–614.
168. Corrigan MH, Gallen CC, Bonura ML, Merchant KM. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. *Biol Psychiatry*. 2004;55:445–451.
169. Kramer MS, Last B, Getson A, Reines SA. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. *Arch Gen Psychiatry*. 1997;54:567–572.
170. Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviere ME, Papillon-Downey C. Placebo-controlled study of the

D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. *Am J Psychiatry*. 1999;156:419–425.

171. Tarazi FI, Zhang K, Baldessarini RJ. Dopamine D4 receptors: beyond schizophrenia. *J Recept Signal Transduct Res*. 2004;24:131–147.
172. Jentsch JD, Taylor JR, Redmond DE Jr, Elsworth JD, Youngren KD, Roth RH. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. *Psychopharmacology (Berl)*. 1999;142:78–84.
173. Mrzljak L, Bergson C, Pappy M, Huff R, Levenson R, Goldman-Rakic PS. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. *Nature*. 1996;381:245–248.
174. Kotecha SA, Oak JN, Jackson MF, et al. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. *Neuron*. 2002;35:1111–1122.
175. Rubinstein M, Cepeda C, Hurst RS, et al. Dopamine D4 receptor-deficient mice display cortical hyperexcitability. *J Neurosci*. 2001;21:3756–3763.
176. Arnsten AF, Murphy B, Merchant K. The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys. *Neuropsychopharmacology*. 2000;23:405–410.
177. Brownman KE, Curzon P, Pan JB, et al. A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats. *Pharmacol Biochem Behav*. 2005;82:148–155.
178. Bernaerts P, Tirelli E. Facilitatory effect of the dopamine D4 receptor agonist PD168,077 on memory consolidation of an inhibitory avoidance learned response in C57BL/6J mice. *Behav Brain Res*. 2003;142:41–52.
179. Wang X, Zhong P, Yan Z. Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. *J Neurosci*. 2002;22:9185–9193.
180. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. *Biol Psychiatry*. 2006;60:141–151.
181. Kopin IJ. Catecholamine metabolism: basic aspects and clinical significance. *Pharmacol Rev*. 1985;37:333–364.
182. Karoum F, Chrapusta SJ, Egan MF. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. *J Neurochem*. 1994;63:972–979.
183. Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. *Proc Natl Acad Sci USA*. 1998;95:9991–9996.
184. Liljequist R, Haapalinna A, Ahlander M, Li YH, Mannisto PT. Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. *Behav Brain Res*. 1997;82:195–202.
185. Gasparini M, Fabrizio E, Bonifati V, Meco G. Cognitive improvement during Tolcapone treatment in Parkinson's disease. *J Neural Transm*. 1997;104:887–894.
186. Watkins P. COMT inhibitors and liver toxicity. *Neurology*. 2000;55:S51–S52; discussion S53–S56.
187. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. *Am J Hum Genet*. 2004;75:807–821.
188. Meyer-Lindenberg A, Kohn PD, Kolachana B, et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. *Nat Neurosci*. 2005;8:594–596.
189. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. *Mol Psychiatry*. 2002;7:405–411.
190. Coon H, Jensen S, Holik J, et al. Genomic scan for genes predisposing to schizophrenia. *Am J Med Genet*. 1994;54:59–71.
191. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. *Am J Hum Genet*. 2003;73:34–48.
192. Fan JB, Zhang CS, Gu NF, et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. *Biol Psychiatry*. 2005;57:139–144.
193. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol-O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. *Am J Psychiatry*. 2003;160:469–476.
194. Munafò MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. *Mol Psychiatry*. 2005;10:765–770.
195. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. *Schizophr Res*. 2007;90:86–96.
196. Apud JA, Mattay V, Chen J, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. *Neuropsychopharmacology*. 2007;32:1011–1020.
197. Willins DL, Deutch AY, Roth BL. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. *Synapse*. 1997;27:79–82.
198. Rodriguez JJ, Garcia DR, Pickel VM. Subcellular distribution of 5-hydroxytryptamine2A and N-methyl-D-aspartate receptors within single neurons in rat motor and limbic striatum. *J Comp Neurol*. 1999;413:219–231.
199. Rodriguez JJ, Doherty MD, Pickel VM. N-methyl-D-aspartate (NMDA) receptors in the ventral tegmental area: subcellular distribution and colocalization with 5-hydroxytryptamine(2A) receptors. *J Neurosci Res*. 2000;60:202–211.
200. Xia Z, Gray JA, Compton-Toth BA, Roth BL. A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. *J Biol Chem*. 2003;278:21901–21908.
201. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. *Brain Res Brain Res Rev*. 2000;31:302–312.
202. Carlsson ML, Martin P, Nilsson M, et al. The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. *J Neural Transm*. 1999;106:123–129.
203. Varty GB, Bakshi VP, Geyer MA. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. *Neuropsychopharmacology*. 1999;20:311–321.
204. Weiner DM, Burstein ES, Nash N, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. *J Pharmacol Exp Ther*. 2001;299:268–276.

205. Doherty MD, Pickel VM. Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. *Brain Res.* 2000;864:176–185.

206. Nocjar C, Roth BL, Pehek EA. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. *Neuroscience*. 2002;111:163–176.

207. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. *Pharmacol Ther.* 2007;113:296–320.

208. Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’? *Clin Neurosci Res.* 2003;3:108–117.

209. Li XM, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. *Psychopharmacology (Berl)*. 1998;136:153–161.

210. Minabe Y, Hashimoto K, Watanabe KI, Ashby CR Jr. Acute and repeated administration of the selective 5-HT(2A) receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study. *Synapse*. 2001;40:102–112.

211. Pehek EA, McFarlane HG, Maguschak K, Price B, Pluto CP. M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. *Brain Res.* 2001;888:51–59.

212. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. *Psychopharmacology (Berl)*. 2004;174:17–24.

213. Poyurovsky M, Koren D, Gonopolsky I, et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. *Eur Neuropsychopharmacol.* 2003;13:123–128.

214. Roth BL, Willins DL, Kristiansen K, Kroeze WK. Activation is hallucinogenic and antagonism is therapeutic: role of 5-HT2A receptors in atypical antipsychotic drug actions. *Neuroscientist*. 1999;5:254–262.

215. Williams GV, Rao SG, Goldman-Rakic PS. The physiological role of 5-HT2A receptors in working memory. *J Neurosci*. 2002;22:2843–2854.

216. Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. *Am J Psychiatry*. 1982;139:1460–1462.

217. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. *Brain Res.* 1985;346:205–230.

218. Hamon M. The main features of the central 5-HT1A receptors. In: Baumgarten HG, Gotner M, eds. *Serotoninergic Neurons and 5-HT Receptors in the CNS*. Berlin, Germany: Springer; 1997:238–268.

219. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. *Neuropharmacology*. 1999;38:1083–1152.

220. Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. *Neuropsychopharmacology*. 1996;14:35–46.

221. Martin-Ruiz R, Puig MV, Celada P, et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. *J Neurosci*. 2001;21:9856–9866.

222. Araneda R, Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. *Neuroscience*. 1991;40:399–412.

223. Schechter LE, Dawson LA, Harder JA. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer’s disease. *Curr Pharm Des.* 2002;8:139–145.

224. Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. *Eur J Pharmacol.* 1998;355:245–256.

225. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. *Neuropsychopharmacology*. 2003;28:1400–1411.

226. Winstanley CA, Chudasama Y, Dalley JW, Theobald DE, Glennon JC, Robbins TW. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. *Psychopharmacology (Berl)*. 2003;167:304–314.

227. Boast C, Bartolomeo AC, Morris H, Moyer JA. 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats. *Neurobiol Learn Mem.* 1999;71:259–271.

228. Yasuno F, Suhara T, Nakayama T, et al. Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. *Am J Psychiatry*. 2003;160:334–340.

229. Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. *Am J Psychiatry*. 2001;158:1722–1725.

230. Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. *Biol Psychiatry*. 2001;49:861–868.

231. Renyi L, Evenden JL, Fowler CJ, et al. The pharmacological profile of (R)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide, a selective 5-hydroxytryptamine(1A) receptor agonist. *J Pharmacol Exp Ther.* 2001;299:883–893.

232. Craig DA, Clarke DE. Pharmacological characterization of a neuronal receptor for 5-hydroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine receptor. *J Pharmacol Exp Ther.* 1990;252:1378–1386.

233. Patel S, Roberts J, Moorman J, Reavill C. Localization of serotonin-4 receptors in the striatonigral pathway in rat brain. *Neuroscience*. 1995;69:1159–1167.

234. Reynolds GP, Mason SL, Meldrum A, et al. 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. *Br J Pharmacol*. 1995;114:993–998.

235. Meneses A, Hong E. Effects of 5-HT4 receptor agonists and antagonists in learning. *Pharmacol Biochem Behav*. 1997;56:347–351.

236. Micale V, Leggio GM, Mazzola C, Drago F. Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia. *Brain Res.* 2006;1121:207–215.

237. Mlinar B, Mascalchi S, Mannaioni G, Morini R, Corradetti R. 5-HT4 receptor activation induces long-lasting EPSP-spike potentiation in CA1 pyramidal neurons. *Eur J Neurosci*. 2006;24:719–731.

238. Cho S, Hu Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. *Exp Neurol*. 2007;203:274–278.

239. Boess FG, Monsma FJ Jr, Carolo C, et al. Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. *Neuropharmacology*. 1997; 36:713–720.

240. Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. *Mol Pharmacol*. 1993;43:320–327.

241. Roth BL, Craig SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. *J Pharmacol Exp Ther*. 1994;268:1403–1410.

242. Bourson A, Borroni E, Austin RH, Monsma FJ Jr, Sleight AJ. Determination of the role of the 5-HT6 receptor in the rat brain: a study using antisense oligonucleotides. *J Pharmacol Exp Ther*. 1995;274:173–180.

243. Bourson A, Boess FG, Bos M, Sleight AJ. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. *Br J Pharmacol*. 1998;125:1562–1566.

244. Rogers DC, Robinson CA, Quilter AJ, Hunter C, Routledge C, Hagan JJ. Cognitive enhancement effects of the selective 5-HT6 antagonist SB-271046. *Br J Pharmacol. suppl.* 1999; 127:22.

245. Routledge C, Bromidge SM, Moss SF, Newman H, Riley G, Hagan JJ. Characterisation of SB-271046: a potent and selective 5-HT6 receptor antagonist. *Br J Pharmacol. suppl.* 1999;127:21.

246. Gustafson EL, Durkin MM, Bard JA, Zgombick J, Brancheck TA. A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5-HT7 receptor in rat brain. *Br J Pharmacol*. 1996;117:657–666.

247. Mengod G, Vilardo MT, Raurich A, Lopez-Gimenez JF, Cortes R, Palacios JM. 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. *Histochem J*. 1996;28:747–758.

248. Neumaier JF, Sexton TJ, Yracheta J, Diaz AM, Brownfield M. Localization of 5-HT(7) receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression. *J Chem Neuroanat*. 2001;21:63–73.

249. Ehlen JC, Grossman GH, Glass JD. In vivo resetting of the hamster circadian clock by 5-HT7 receptors in the suprachiasmatic nucleus. *J Neurosci*. 2001;21:5351–5357.

250. Lovenberg TW, Baron BM, de Lecea L, et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. *Neuron*. 1993;11:449–458.

251. Thomas DR, Melotto S, Massagrande M, et al. SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. *Br J Pharmacol*. 2003;139:705–714.

252. Manuel-Apolinar L, Meneses A. 8-OH-DPAT facilitated memory consolidation and increased hippocampal and cortical cAMP production. *Behav Brain Res*. 2004;148:179–184.

253. Roberts AJ, Krucker T, Levy CL, Slanina KA, Sutcliffe JG, Hedlund PB. Mice lacking 5-HT receptors show specific impairments in contextual learning. *Eur J Neurosci*. 2004; 19:1913–1922.

254. Bickmeyer U, Heine M, Manzke T, Richter DW. Differential modulation of I(h) by 5-HT receptors in mouse CA1 hippocampal neurons. *Eur J Neurosci*. 2002;16:209–218.

255. Tokarski K, Zahorodna A, Bobula B, Hess G. 5-HT7 receptors increase the excitability of rat hippocampal CA1 pyramidal neurons. *Brain Res*. 2003;993:230–234.

256. Arnsten AF. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. *Psychopharmacology (Berl)*. 2004;174:25–31.

257. Fields RB, Van Kammen DP, Peters JL, et al. Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings. *Schizophr Res*. 1988;1:417–423.

258. Friedman JI, Adler DN, Temporini HD, et al. Guanfacine treatment of cognitive impairment in schizophrenia. *Neuropsychopharmacology*. 2001;25:402–409.

259. Millan MJ, Gobert A, Newman-Tancredi A, et al. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. *J Pharmacol Exp Ther*. 2000;292:38–53.

260. Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. *Neuroscience*. 1998;84:413–429.

261. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. Idoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. *Br J Psychiatry*. 1996;168:571–579.

262. Rao SG, Williams GV, Goldman-Rakic PS. Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory. *J Neurosci*. 2000;20:485–494.

263. Benes FM, Vincent SL, Marie A, Khan Y. Up-regulation of GABA(A) receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. *Neuroscience*. 1996;75: 1021–1031.

264. Blum BP, Mann JJ. The GABAergic system in schizophrenia. *Int J Neuropsychopharmacol*. 2002;5:159–179.

265. Lewis DA, Pierri JN, Volk DW, Melchitzky DS, Woo TU. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. *Biol Psychiatry*. 1999;46: 616–626.

266. De Luca V, Muglia P, Masellis M, Jane Dalton E, Wong GW, Kennedy JL. Polymorphisms in glutamate decarboxylase genes: analysis in schizophrenia. *Psychiatr Genet*. 2004;14:39–42.

267. Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. *J Neurosci*. 2003;23:6315–6326.

268. Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. *Psychopharmacology (Berl)*. 2004;174: 143–150.

269. Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. *Arch Neurol*. 2006;63:1372–1376.

270. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. *Nat Rev Neurosci*. 2005;6:312–324.

271. de Haas SL, de Visser SJ, van der Post JP, et al. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA α 2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. *J Psychopharmacol*. 2006; doi:10.1177/0269881106072343.

272. Dawson GR, Maubach KA, Collinson N, et al. An inverse agonist selective for alpha5 subunit-containing GABA_A receptors enhances cognition. *J Pharmacol Exp Ther.* 2006; 316:1335–1345.

273. Collinson N, Atack JR, Laughton P, Dawson GR, Stephens DN. An inverse agonist selective for alpha5 subunit-containing GABA_A receptors improves encoding and recall but not consolidation in the Morris water maze. *Psychopharmacology (Berl).* 2006;188:619–628.

274. Atack JR, Bayley PJ, Seabrook GR, Wafford KA, McKernan RM, Dawson GR. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABA_A receptors. *Neuropharmacology.* 2006;51:1023–1029.

275. Chambers MS, Atack JR, Carling RW, et al. An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABA_A alpha5 receptors with cognition enhancing properties. *J Med Chem.* 2004;47:5829–5832.

276. Glykys J, Mody I. Hippocampal network hyperactivity after selective reduction of tonic inhibition in GABA A receptor alpha5 subunit-deficient mice. *J Neurophysiol.* 2006;95: 2796–2807.

277. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. *J Pharmacol Exp Ther.* 1976;197:517–532.

278. Su TP. Evidence for sigma opioid receptor: binding of [³H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. *J Pharmacol Exp Ther.* 1982;223:284–290.

279. Hanner M, Moebius FF, Flandorfer A, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. *Proc Natl Acad Sci USA.* 1996;93:8072–8077.

280. Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. *Science.* 1988;240:219–221.

281. Su TP. Delineating biochemical and functional properties of sigma receptors: emerging concepts. *Crit Rev Neurobiol.* 1993;7:187–203.

282. Monnet FP, Debonnel G, Junien JL, De Montigny C. N-methyl-D-aspartate-induced neuronal activation is selectively modulated by sigma receptors. *Eur J Pharmacol.* 1990; 179:441–445.

283. Ishihara K, Sasa M. [Modulation of neuronal activities in the central nervous system via sigma receptors]. *Nihon Shinkei Seishin Yakurigaku Zasshi.* 2002;22:23–30.

284. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. *CNS Drugs.* 2004; 18:269–284.

285. Zou LB, Yamada K, Nabeshima T. Sigma receptor ligands (+)-SKF10,047 and SA4503 improve dizocilpine-induced spatial memory deficits in rats. *Eur J Pharmacol.* 1998;355: 1–10.

286. Bologa L, Sharma J, Roberts E. Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures. *J Neurosci Res.* 1987;17:225–234.

287. Compagnone NA, Mellon SH. Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. *Proc Natl Acad Sci USA.* 1998;95: 4678–4683.

288. Roberts E, Bologa L, Flood JF, Smith GE. Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. *Brain Res.* 1987;406:357–362.

289. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. *J Neurosci.* 1996;16:1193–1202.

290. Debonnel G, Bergeron R, de Montigny C. Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors. *J Endocrinol. suppl.* 1996;150:S33–S42.

291. Flood JF, Smith GE, Roberts E. Dehydroepiandrosterone and its sulfate enhance memory retention in mice. *Brain Res.* 1988;447:269–278.

292. Flood JF, Morley JE, Roberts E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. *Proc Natl Acad Sci USA.* 1992;89:1567–1571.

293. Maurice T, Junien JL, Privat A. Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via sigma 1-receptors. *Behav Brain Res.* 1997;83: 159–164.

294. Reddy DS, Kulkarni SK. The effects of neurosteroids on acquisition and retention of a modified passive-avoidance learning task in mice. *Brain Res.* 1998;791:108–116.

295. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. *Arch Gen Psychiatry.* 2003;60:133–141.

296. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. *Neuron.* 2006;52:139–153.

297. Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. *Mol Psychiatry.* 2006;11:11–17.

298. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. *Biol Psychiatry.* 1999;46:729–739.

299. Thome J, Foley P, Riederer P. Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. Review article. *J Neural Transm.* 1998;105:85–100.

300. Stahl SM. When neurotrophic factors get on your nerves: therapy for neurodegenerative disorders. *J Clin Psychiatry.* 1998;59:277–278.

301. Zarate J, Carlos A, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. *Biol Psychiatry.* 2006;59:1006–1020.

302. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. *Curr Drug Targets.* 2006;7:1421–1434.

303. Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. *Curr Opin Investig Drugs.* 2007;8:54–59.

304. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. *J Pharmacol Exp Ther.* 2007;320:1–13.

305. Ghanouni P, Gryczynski Z, Steenhuis JJ, et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. *J Biol Chem.* 2001;276:24433–24436.